Healthcare Industry News: stent thrombosis
News Release - January 20, 2008
CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-FATLANTA, Jan. 20 (HSMN NewsFeed) -- CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin PolyzeneŽ-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).
Corrado Tamburino, MD, President of the Italian Society of Interventional Cardiology, Chief of Interventional Cardiology at Ferrarotto Hospital and Full Professor of Cardiology at the University of Catania is Principal Investigator for the ATLANTA study. Dr. Tamburino noted, "I perform many angioplasties in each single day, many, and I am totally impressed by the performance of this stent in a very complex patient population. No thrombosis. Low binary restenosis. No MIs. This may be an answer to the problems we are facing with other stent systems."
The CATANIA(TM) Stent System with NanoThin PolyzeneŽ-F, dubbed "The CAT" by cardiologists who have used the product, has completed CE Marking and is available for sale anywhere the CE Mark is accepted. Advantages include:
-- Early and complete vessel healing, as early as 30 days.
-- Patients can discontinue dual anti-platelet therapy after only one month.
-- Protection from stent thrombosis
-- The PolyzeneŽ-F surface treatment is bacterial-resistant
"The FDA has cautioned physicians about a small but significant increased risk of stent thrombosis for patients with drug-eluting stents. Now, Britain's National Institute for Health and Clinical Excellence is considering restrictions on DES because they are not cost-effective for most patients and because of uncertainties about safety. PolyzeneŽ-F seems to solicit a positive biological response that treats the stent as accepted part of the vessel. As a result, 'The CAT' patients have excellent outcomes and can be free from the medical complications and financial burden associated with indefinite anti-platelet therapy," stated Thomas A. Gordy, President and Chief Executive Officer.
About CeloNova BioSciences, Inc.
Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, PolyzeneŽ-F. PolyzeneŽ-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin PolyzeneŽ-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit www.celonova.com.
Source: CeloNova BioSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.